Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH3127 vs valsartan for primary mild to moderate hypertension
CTR20210369Phase 3Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sitokiren in essential hypertension, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Mar 2021; status: completed.
02
Drugs
sitokiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20210369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210369.